ICN Pharmaceuticals Inc 500 mln dlrs cash 1.50 billion dlrs available credit intend buy pharmaceutical company Chairman Milan Panic said. At company's annual meeting acquisition 24 months. "The company nearly billion dlrs available acquisition today" Panic add "We investigate companies." One company study possibly acquire friendly basis said. Panic intend seek board approval repurchase mln ICN common shares. Discussing possibility acquisition Panic purchase necessary ICN's current marketing capability sufficient support distribution company's product ICN's expectation market growth worldwide. ICN's principal product ribavirin know Virazole. The drug market country described broad-based anti-viral. The company application include treatment type hepatitis herpes influenza childhood disease hemorrhagic fevers. ICN focus consirable investor attention recent month Virazole undergone clinical trial treatment AIDS-related diseases. Panic discus drug regard AIDS Food Drug Administration completes review data submit company. He investigation drug conduct House Subcommittee continuing. The subcommittee FDA acknowledge conduct separate investigation determine whether ICN witheld data FDA adverse reaction drug. Virazole approve marketing U.S. aerosol form treatment infection strike infant call respiratory syncytial virus. Reuter 